NASDAQ:ISTA ISTA Pharmaceuticals (ISTA) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free ISTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ISTA Pharmaceuticals alerts: Email Address Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About ISTA Pharmaceuticals Stock (NASDAQ:ISTA)ISTA Pharmaceuticals, Inc. (ISTA) is a commercial-stage, multi-specialty pharmaceutical company. The Company is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. ISTA in-licenses or acquires new products and technologies to add to its internal development. Its products and product candidates seek to treat allergy and diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. It has four products available for sale in the United States and Puerto Rico: BROMDAY (bromfenac ophthalmic solution) 0.09%, BEPREVE (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL (timolol maleate ophthalmic solution) 0.5% and VITRASE (hyaluronidase injection).Read More Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… ISTA Stock News HeadlinesApril 26, 2024 | finance.yahoo.comInvensify Introduces the Industry’s Most Energy Efficient Cold Chain Shipping TransporterMarch 27, 2024 | seekingalpha.comCRVS Corvus Pharmaceuticals, Inc.October 3, 2023 | finance.yahoo.comMicrotek Laboratories Introducing a Universal Conditioning, Year-Round, Controlled Room Temperature (CRT) Shipping SolutionMay 6, 2023 | benzinga.comRocket Pharmaceuticals Stock (NASDAQ:RCKT), Analyst Ratings, Price Targets, PredictionsMarch 13, 2023 | finance.yahoo.comVital Pharmaceuticals Announces New Interim Chief Executive OfficerOctober 18, 2022 | markets.businessinsider.comCSafe Continues Expansion of Its Temperature-Controlled Shipping Solutions Portfolio with Introduction of Advanced Reusable Pallet ShipperSeptember 25, 2022 | fool.comJazz Pharmaceuticals (NASDAQ: JAZZ)September 19, 2022 | nz.finance.yahoo.comHarpoon Therapeutics Appoints Lauren Silvernail to Board of DirectorsSeptember 8, 2022 | thestreet.comStocks End Lower on Tepid U.S. Data, Energy Sector PullbackJune 15, 2022 | finance.yahoo.comVisiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic AdvisorJune 9, 2022 | yahoo.comSana Expands Affordable Health Plans for Small Businesses to IndianaJune 7, 2022 | finance.yahoo.comNationally Recognized Ophthalmologist Ehsan Sadri, M.D. FACS and Industry Veteran Tom Mitro Appointed to Visiox's Board of DirectorsDecember 10, 2021 | msn.comSealed Air Singapore provides innovative and sustainable packaging solutionsDecember 9, 2021 | finanznachrichten.deFuture Market Insights: Corrugated Boxes Market to Surpass US$ 128.3 Bn as Recycled Boxes Demand Increases by 4.7%: FMIDecember 9, 2021 | yahoo.comCorrugated Boxes Market to Surpass US$ 128.3 Bn as Recycled Boxes Demand Increases by 4.7%: FMINovember 8, 2021 | finance.yahoo.comI-MED Pharma USA Announces Brent Jones as Chief Commercial OfficerSeptember 8, 2021 | msn.comPhilippines to establish 1st simulation packaging testing labJuly 28, 2021 | marketwatch.comGlobal Package and Container Testing Market Market 2021 Key Players Analysis, Segmentation, Industry Size, Growth, Trend and Forecast by 2026See More Headlines Receive ISTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ISTA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ISTA CUSIPN/A CIK930553 Webwww.istavision.com Phone+1-949-7886000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ISTA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ISTA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.